surpass cvot tirzepatide 💡 New insight in diabetes care: In patients with T2DM and ASCVD, the SURPASS-CVOT trial found that was noninferior to dulaglutide for major cardiovascular events (12.2% vs 13.1%; HR 0.92). What ACC 26: SURPASS-CVOT - Tirzepatide

If a dose is missed, it should be administered within 4 days of the scheduled dose

Irritable bowel syndrome and stress-related psychiatric co-morbidities: focus on early life stress

The good news is that tirzepatide fatigue responds well to simple lifestyle adjustments

A: FDA-approved Mounjaro & Zepbound are proven through SURMOUNT trials (~20% weight loss)

no enrollment or membership fee per published terms 6-month offer: Commercial satisfaction policy with specific adherence and documentation requirements - not a medical guarantee of weight loss results Eligibility (brand-stated): BMI 30, or BMI 27 with a qualifying comorbidity (type 2 diabetes, hypertension, dyslipidemia, sleep apnea, cardiovascular disease)

But the scientific reality is more nuanced than the product pages suggest